Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended- release formulations in its clinical management

Substance Abuse: Research and Treatment

Volumn 6, Issue 1, 2012, Pages 115-133

  Reece, Albert Stuart ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aging; Chronic opiate agonism; Extended release naltrexone; Immunostimulation; Immunosuppression; Naltrexone implant; Pathophysiology; Toxicopathology

Indexed keywords

BUPRENORPHINE; INFLAMMASOME; INTERLEUKIN 1; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; OPIATE; PLACEBO; TOLL LIKE RECEPTOR 4;

APPETITE; BINDING AFFINITY; CARCINOGENESIS; CELL CONTACT; CHRONIC OPIATE ADDICTION; DEPRESSION; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; EXTENDED RELEASE FORMULATION; HUMAN; IMMUNOSTIMULATION; INDIGESTION; INJECTION SITE REACTION; INSOMNIA; LIFESTYLE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; OPIATE ADDICTION; PAIN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STEM CELL; WITHDRAWAL SYNDROME; WOUND INFECTION;

EID: 84867561237     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/SART.S9031     Document Type: Review

References (121)

1. Dole VP, Nyswander M. A Medical Treatment for Diacetylmorphine (Heroin) Addiction. A Clinical Trial with Methadone Hydrochloride. JAMA. Aug 23, 1965;193:646-50.
2. Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry. May 2012;169(5):531-6.
3. Joint United Nations Program on HIV/AIDS (UNAIDS). 2008 Report on the global AIDS epidemic. UNAIDS. http://www.unaids.org/en/dataanalysis/knowyourepidemic/epidemiologypublications/2008reportontheglobalaidse pidemic/. Accessed 2012.
4. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ Clinical Research ed. 2010;341:c3172.
5. McKeganey N. Abstinence and harm reduction: can they work together? Int J Drug Policy. May 2011;22(3):194-5.
6. McKeganey N. Community treatments for heroin and crack cocaine addiction. Lancet. Jan 23, 2010;375(9711):278; author reply 278-9.
7. Schecter A. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone. Am J Drug Alcohol Abuse. 1980;7(1):1-18.
8. O'Connor PG, Waugh ME, Carroll KM, Rounsaville BJ, Diagkogiannis IA, Schottenfeld RS. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med. May 1995;10(5):255-60.
9. Julius D. NIDA's naltrexone research program. NIDA Res Monograph. Sep 1976;9:5-11.
10. Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry. Mar 1978;35(3):335-40.
11. Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J Clin Forensic Med. Jun 1996;3(2):87-92.
12. Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. Oct 2010;12(5):448-53.
13. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry. Sep 1984;45(9 Pt 2):46-8.
14. Olsen JL, Kincl FA. A review of parenteral sustained-release naltrexone systems. NIDA Res Monogr. 1981;28:187-93.
15. Olsen JL, Kincl FA. A Review of parenteral sustained release naltrexone systems. In: Services HAH, editor. NIDA Research Monograph. Rockville, Maryland: National Instutute of Drug Abuse; 1980;28:187-64.
16. Yolles S, Leafe TD, Woodland JH, Meyer FJ. Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites. J Pharm Sci. Feb 1975;64(2):348-9.
17. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. Feb 2006;63(2):210-8.
18. Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry. Mar 10, 2010.
19. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a doubleblind, placebo-controlled, multicentre randomised trial. Lancet. Apr 30, 2011;377(9776):1506-13.
20. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. Oct 2009;66(10):1108-15.
21. Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after inpatient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. Jun 2009;194(6):541-6.
22. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioidinduced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. Nov 2009;30(11):581-91.
23. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. Feb 2002;38(3): 351-76.
24. Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N. Morphine enhances macrophage apoptosis. J Immunol. Feb 15, 1998;160(4):1886-93.
25. Bernard B. Lecons Sur Le Diabete et la Glycogenese Animal. Paris: Cours de Medecine; 1877:1.
26. Snyder SH. The opiate receptor. Neurosci Res Program Bull. Aug 1975; 13 Suppl:1-27.
27. Adams JU, Holtzman SG. Pharmacologic characterization of the sensitization to the rate-decreasing effects of naltrexone induced by acute opioid pretreatment in rats. J Pharmacol Exp Ther. May 1990;253(2): 483-9.
28. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Williams Textbook of Endocrinology. 11th ed. New York: Saunders Elsevier; 2007:1.
29. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. May 24, 2001;411(6836):480-4.
30. Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins. Pharmacol Res. Jan 2009;59(1):13-47.
31. Bomberg EM, Grace MK, Levine AS, Olszewski PK. Functional interaction between nociceptin/orphanin FQ and alpha-melanocyte-stimulating hormone in the regulation of feeding. Peptides. Jul 2006;27(7):1827-34.
32. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav. Jul 2002;76(3):365-77.
33. Reece AS. Hypothalamic opioid-melanocortin appetitive balance and addictive craving. Med Hypotheses. Jan 2011;76(1):132-7.
34. al'Absi M, France C, Harju A, France J, Wittmers L. Adrenocortical and nociceptive responses to opioid blockade in hypertension-prone men and women. Psychosom Med. Mar-Apr 2006;68(2):292-8.
35. Purkayastha S, Zhang G, Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappaB. Nat Med. Jul 2011;17(7):883-7.
36. Anderson KV, Bokla L, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell. Oct 1985;42(3):791-8.
37. Imler JL, Zheng L. Biology of Toll receptors: lessons from insects and mammals. J Leukoc Biol. Jan 2004;75(1):18-26.
38. Fourgeaud L, Boulanger LM. Synapse remodeling, compliments of the complement system. Cell. Dec 14, 2007;131(6):1034-6.
39. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron. Oct 15, 2009;64(1):93-109.
40. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. Oct 15, 2009;64(1):61-78.
41. El-Hage N, Podhaizer EM, Sturgill J, Hauser KF. Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol Invest. 2011;40(5):498-522.
42. Neri S, Bruno CM, Pulvirenti D, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl). May 2005;179(3):700-4.
43. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. Sep-Oct 2004;11(5):354-65.
44. Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006; No. 1.
45. Reece AS. High Sensitivity CRP in Opiate Addiction: Relative and Age-Dependent Elevations. Cardiovasc Toxicol. In Press; 2012.
46. Reece AS. Relative and Age Dependent Stimulation of Soluble and Cellular Immunity in Opiate Dependence. J Addict Med. In Press; 2012.
47. Kim do K, Hwang CK, Wagley Y, Law PY, Wei LN, Loh HH. p38 mitogenactivated protein kinase and PI3-kinase are involved in up-regulation of mu opioid receptor transcription induced by cycloheximide. J Neurochem. Mar 2011;116(6):1077-87.
48. Garcia-Fuster MJ, Ramos-Miguel A, Miralles A, Garcia-Sevilla JA. Opioid receptor agonists enhance the phosphorylation state of Fas-associated death domain (FADD) protein in the rat brain: functional interactions with casein kinase Ialpha, Galpha(i) proteins, and ERK1/2 signaling. Neuropharmacology. Oct 2008;55(5):886-99.
49. Grzanna R, Brown RM. NIDA Research Monograph 125: Activation of Intermediate Early Genes by Drugs of Abuse. In: National Institutes of Drug Abuse, ed. Bethesda, Maryland: NIH; 1993;125:1-220.
50. Chao CC, Hu S, Molitor TW, et al. Morphine potentiates transforming growth factor-beta release from human peripheral blood mononuclear cell cultures. J Pharmacol Exp Ther. Jul 1992;262(1):19-24.
51. Stefano GB, Kream RM. Dopamine, morphine, and nitric oxide: an evolutionary signaling triad. CNS Neurosci Ther. Jun 2010;16(3):e124-37.
52. Delves P, Martin SJ, Burton DR, Roitt IM. Roitt's Essential Immunology. 12th ed: Wiley-Blackwell; 2011:1.
53. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. Sep 2011;63(3):772-810.
54. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem. 2009;78:743-68.
55. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. Mar 2007;28(3):102-7.
56. van Doorn R, Lopes Pinheiro MA, Kooij G, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflammation. Jun 20, 2012;9(1):133.
57. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. Sep 2011;12(64):213-28.
58. Wang X, Loram LC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A. Apr 17, 2012; 109(16):6325-30.
59. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. Apr 1, 2001;62(2):111-23.
60. Borner C, Hollt V, Kraus J. Mechanisms of the inhibition of nuclear factor-kappaB by morphine in neuronal cells. Mol Pharmacol. Apr 2012; 81(4):587-97.
61. Negishi H, Yanai H, Nakajima A, et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol. 2012;13(7):659-66.
62. Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science. Feb 11, 2011;331(6018):775-8.
63. Reece AS. Chronic immune stimulation as a contributing cause of chronic disease in opiate addiction including multi-system ageing. Med Hypotheses. Dec 2010;75(6):613-9.
64. Fauci AS, Braunwald E, Kapser DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw Hill; 2008; No. 1.
65. Murphy Kenneth. Janeway's Immunobiology. 8th ed. London: Garland Science; 2012:1.
66. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Tolllike receptor signalling. Nat Rev Immunol. Mar 2011;11(3):163-75.
67. Fan W, Morinaga H, Kim JJ, et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. Dec 15, 2010;29(24):4223-36.
68. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell. Feb 25, 2005;120(4):473-82.
69. Tilich M, Arora RR. Modulation of toll-like receptors by insulin. Am J Ther. Sep 2011;18(5):e130-7.
70. Tannahill GM, O'Neill LA. The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3. FEBS letters. Jun 6, 2011;585(11):1568-72.
71. Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. May 2000;11(5): 1859-74.
72. Reece AS, Davidson P. Deficit of circulating stem-progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy. 2007;2:19-28.
73. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9-15.
74. Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ Clinical Research ed. 2012;344:e2502.
75. Tilich M, Arora RR. Modulation of Toll-Like Receptors by Insulin. Am J Ther. 2011;18(5):e130-7. 110.1097/MJT.1090b1013e3181e1071fa1090.
76. Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs. Aug 2007; 16(8):1285-94.
77. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. Mar 2004;9(1):59-65.
78. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry. Jan 1, 2008;32(1):23-8.
79. Hulse GK, Arnold-Reed DE, Ngo H, Reece AS. Naltrexone Implants in the Treatment of Heroin Addiction. In: McKenna CR, editor. Trends in Substance Abuse Research. New York: Nova; 2007;1:71-88.
80. Randall D, Degenhardt L, Vajdic CM, et al. Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health. Jun 2011;35(3):220-5.
81. Sadeghian S, Graili P, Salarifar M, Karimi AA, Darvish S, Abbasi SH. Opium consumption in men and diabetes mellitus in women are the most important risk factors of premature coronary artery disease in Iran. Int J Cardiol. May 14, 2010;141(1):116-8.
82. Sadeghian S, Dowlatshahi S, Karimi A, Tazik M. Epidemiology of opium use in 4398 patients admitted for coronaryAust N Z J Public Health. artery bypass graft in Tehran Heart Center. J Cardiovasc Surg (Torino). Feb 2011; 52(1):140-1.
83. Sadeghian S, Darvish S, Davoodi G, et al. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. Oct 2007;14(5): 715-7.
84. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. May 15, 2005; 40(10):1492-9.
85. Howard AA, Floris-Moore M, Lo Y, Arnsten JH, Fleischer N, Klein RS. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med. Sep 2006;7(6):389-96.
86. Kolarzyk E, Pach D, Wojtowicz B, Szpanowska-Wohn A, Szurkowska M. Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przeglad Lekarski. 2005;62(6):373-7.
87. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis. 2003;37 Suppl 2:S132-6.
88. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity-a review. Neuropeptides. Dec 2006;40(6):375-401.
89. Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. Dec 1, 2006;85(3):258-62.
90. Isbell H. The Effect of Morphine Addiction on Blood, Plasma, and " Extracellular" Fluid Volumes in Man. Public Health Reports. 1947;62(42): 1499-513.
91. Zhou Y, Spangler R, Maggos CE, et al. Hypothalamic-pituitary-adrenal activity and pro-opiomelanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J Endocrinol. Nov 1999; 163(2):261-7.
92. Schlussman SD, Zhou Y, Johansson P, et al. Effects of the androgenic anabolic steroid, nandrolone decanoate, on adrenocorticotropin hormone, corticosterone and proopiomelanocortin, corticotropin releasing factor (CRF) and CRF receptor 1 mRNA levels in the hypothalamus, pituitary and amygdala of the rat. Neurosci Lett. Apr 28, 2000; 284(3):190-4.
93. Reece AS. Differing age related trajectories of dysfunction in several organ systems in opiate dependence. Aging Clin Exp Res. Feb 21, 2011.
94. Reece AS. Hair graying in substance addiction. Arch Dermatol. Jan 2007; 143(1):116-8.
95. Reece AS. Dental Health in Addiction. Aust Dent J. 2009;54(2):185-6.
96. Sadeghi A, Behmard S. Cancer of the bladder in Southern Iran. Cancer. Jul 1978;42(1):353-6.
97. Mousavi MR, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. Nov 2003;113(11):1939-43.
98. Ghavamzadeh A, Moussavi A, Jahani M, Rastegarpanah M, Iravani M. Esophageal cancer in Iran. Semin Oncol. Apr 2001;28(2):153-7.
99. Becker WC, O'Connor PG. The safety of opioid analgesics in the elderly: new data raise new concerns: comment on "The comparative safety of opioids for nonmalignant pain in older adults". Ann Intern Med. Dec 13, 2010;170(22):1986-8.
100. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. Jan 19, 2010; 152(2):85-92.
101. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs. Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. Arch Gen Psychiatry. 2012; 69(9):973-81.
102. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy. 2007;2:35-49.
103. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence. Lancet. Aug 20, 2011;378(9792):665; author reply 666.
104. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr. 1981;28:147-58.
105. Hulse GK, Stalenberg V, McCallum D, et al. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release. Nov 2, 2005;108(1):43-55.
106. Farid WO, McCallum D, Tait RJ, Dunlop SA, Hulse GK. Minor pathological changes are induced by naltrexone-poly(DL-lactide) implants in pregnant rats. J Biomed Mater Res A. Dec 15, 2009;91(4):964-74.
107. Hulse GK, Low VH, Stalenberg V, et al. Biodegradability of naltrexonepoly(DL) lactide implants in vivo assessed under ultrasound in humans. Addict Biol. Sep 2008;13(3-4):364-72.
108. Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Feb 5, 2007;186(3):152-3.
109. Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet. April 30, 2011;377(9776):1468-70.
110. Batey RG. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):55; author reply 56-7.
111. Brewer CL. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):55; author reply 56-7.
112. Hulse GK, Tait RJ. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):54; author reply 56-7.
113. Khong E, Choy W. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):56; author reply 56-7.
114. Kunoe N, Waal H. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):56; author reply 56-7.
115. Sim MG. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust. Jul 2, 2007;187(1):54; author reply 56-7.
116. Woody GE, Metzger DS. Injectable extended-release naltrexone for opioid dependence. Lancet. Aug 20, 2011;378(9792):664-5; author reply 666.
117. Throckmorton DC, Temple R, Rappaport BA, Roca R, Winchell CJ. Injectable extended-release naltrexone for opioid dependence. Lancet. Aug 20, 2011;378(9792):665-6; author reply 666.
118. Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat. Sep 2008;35(2):116-24.
119. Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol. Sep 2003;8(3):337-42.
120. Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. Sep 1, 2005;79(3):351-7.
121. Reece AS. Favourable mortality profile of naltrexone implants for opiate addiction. Journal of Addictive Diseases. 2010;29(1):30-50.